Is dabrafenib included in medical insurance?

Dabrafenib (Dabrafenib) is a targeted anti-cancer drug developed by GlaxoSmithKline. The trade name is Tafinlar. It is mainly used to treat melanoma patients carrying BRAF V600 mutations. The BRAF gene is one of the oncogenes. When mutated, it may cause normal cells to transform into tumor cells. Dabrafenib inhibits tumor growth by inhibiting the kinase activity of BRAF V600 mutations and blocking cell proliferation signals.

Dabrafenib is usually taken orally in capsule form. The recommended dose is 150 mg twice daily. Take it at least 1 hour before or 2 hours after a meal to maintain the stability of drug absorption. The drug has shown significant efficacy in clinical trials and can significantly extend the progression-free survival of patients and improve the objective response rate. However, dabrafenib may also cause a series of adverse reactions, including fever, rash, diarrhea, nausea, etc. Patients need to pay close attention to physical reactions when using it and use the medication rationally under the guidance of a doctor.

Dabrafenib has not only made an important breakthrough in the treatment of melanoma, but is also exploring its application potential in other types of tumors. For example, dabrafenib combined with trametinib has been approved for the treatment of metastatic non-small cell lung cancer with BRAF V600 mutations, showing good efficacy and safety. In addition, dabrafenib is also being studied for the treatment of other types of tumors such as thyroid cancer and cholangiocarcinoma.

Dabrafenib has been successfully launched on the Chinese market and has successfully entered the medical insurance system, reducing financial pressure on patients. In China, the original drug of dabrafenib is available in two specifications: 75mg 120 tablets and 50mg 120 tablets. The price of the 75mg specification after medical insurance reimbursement is about 12,000 yuan. In addition, dabrafenib has also attracted much attention in overseas markets, and there are two versions: original research and generic versions. Novartis' original 75 mg 120-capsule drug is priced at 11,000 yuan per box in Turkey, while many generic versions of the same specifications on the market are generally priced around 2,700 yuan.

In general, dabrafenib, as a targeted anti-cancer drug, provides new treatment options for tumor patients carryingBRAF V600 mutations, and is continuously expanding its clinical application scope.